Drug Trial Radar · NCT07473154
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Apr 10, 2026
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Quell Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether QEL-005 is safe, how well people tolerate it, and whether it may help reduce disease activity or improve symptoms. QEL-005 is made from a participant's own white blood cells (autologous cells). These cells are collected and then changed in a laboratory using genetic methods to create specialized immune cells called CAR-T regulatory cells that target a protein on B cells called CD19. These modified cells are then given back to the participant by intravenous (IV) infusion. To take part, eligible participants will first have a procedure called leukapheresis, where some of their white blood cells are removed from the blood. The study team will use these cells to manufacture QEL005. After QEL005 is ready, participants will receive an IV infusion of their modified cells, stay in hospital overnight for monitoring, and will then be followed closely in the clinic. Throughout the trial, participants will have regular safety checks, which may include blood tests, imaging scans, questionnaires about symptoms and daily functioning, and biopsies taken from involved tissues, to help understand how QEL005 is working in the body. Detailed follow up will be for 1 year after QEL-005 infusion, and there is long-term follow up for a total of 15 years, which is standard for cell therapies. The information from this Phase 1/2 study will help determine an appropriate dose and dosing schedule of QEL005 for future studies.
Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Rheumatoid Arthritis (RA)
- Systemic Sclerosis (SSc)
- Autoimmune Rheumatologic Disease
Interventions
QEL-005Drug
QEL-005 is an autologous cell therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against the B cell marker CD19. Treatment will be given via an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- D2TRA & SSc: Incidence of Protocol-Defined Dose Limiting Toxicities (DLTs) to Assess Safety and Tolerability (Dose Escalation Phase Only)Time frame: up to 28 days post-infusion
- D2TRA & SSc: Incidence and grade of treatment-emergent adverse events (TEAEs), adverse events (AEs) and adverse events of special interest (AESIs)Time frame: From time of signing the informed consent form (ICF) through to week 52
- D2TRA & SSc: Incidence of clinically significant abnormalities in safety laboratory parameters, electrocardiogram (ECG) findings, and vital signsTime frame: Up to week 52
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
University Hospital Düsseldorf
Düsseldorf, Germany · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Not yet recruiting
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom · Recruiting
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom · Recruiting
Guy's & St Thomas NHS Foundation Trust
London, United Kingdom · Not yet recruiting
Royal Free London NHS Foundation Trust
London, United Kingdom · Recruiting
Manchester University NHS Foundation Trust
Manchester, United Kingdom · Not yet recruiting
Newcastle Upon Tyne NHS Foundation Trust
Newcastle, United Kingdom · Recruiting
University of Oxford - The Kennedy Institute
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.